Study Description
This is a multicenter, randomized, placebo- and active-controlled, parallel-group,
24-week trial to investigate the efficacy, safety, and tolerability of XXB750 in
participants with HFrEF/HFmrEF. Eligible participants will be randomized to receive either subcutaneous (s.c.) XXB750 or
placebo; or sacubitril/valsartan for 16 weeks, and then followed-up for 8 weeks
Interventions
Placebo
Sacubitril/valsartan
XXB750 High Dose
XXB750 Low dose
XXB750 Medium Dose
Eligibility Criteria
Inclusion Criteria:
- Current symptom(s) of HF NYHA class II-III and LVEF < 50%
- Elevated NT-proBNP levels at screening.
- Receiving standard of care background HF therapy.
Exclusion Criteria:
- Current acute decompensated HF or hospitalization for HF within 3 months prior to
screening.
- Current symptomatic hypotension (for example dizziness/presyncope).
- K+ > 5.4 mmol/L at screening
- eGFR < 30 mL/min/1.73m2 at screening
Other protocol-specific criteria may apply.
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.